NLS Pharmaceutics Ltd. (NLS) Announces Notice of Allowance of two new Patents in North America Covering Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy further bolstering its Patent Portfolio

Source :: GlobeNewswire. July 3, 2019
Publication Year :: 2019
Abstract: STANS, Switzerland, Jul 03, 2019 (GLOBE NEWSWIRE via COMTEX) -- NLS Pharmaceutics Ltd. (NLS), a Swiss biotech firm focusing on the development of novel treatments for the Central Nervous System [...]

Subjects :: Mazindol -- Intellectual property
Attention deficit hyperactivity disorder
Patents
Nervous system diseases
Narcolepsy
Hyperactivity
Intellectual property
Trademarks
Biotechnology
Hypersomnia
Biotechnology industries
Central nervous system
Patent/copyright issue
Banking, finance and accounting industries
Business

Tools